InvestorsHub Logo

29YEARINVESTOR

08/28/18 5:38 AM

#127988 RE: SkittlesRed #127985

I Agree It's accumulation Due to the latest developments with UNGS Greater Cannabis Co "GCAN". However I and Many others will not be adding and can not recommend anyone buy UNGS, Until Wayne Rescinds the Proposed R/S that never happened and I think never will. But the only way to be sure is to see a official Filing Rescinding it like Wayne did in 2015. Which helped cause a run and IMO would help cause another UNGS 2018 run, Like UNGS had Last year that lasted from January thru March.
That FUN Run had very high volume.
It's not needed with all the GCAN developments and would be perfect timing for those who missed or where not here for UNGS GCAN Dividend to still Own a piece of GCAN through UNGS before GCAN starts Trading! Since UNGS retained 19.99% of GCAN after giving Loyal Shareholders the other 80.01%.

The new website will likely be GcanRx. Gwinis got this directly from the New CEO's page on linkedin. With Rx in the name, I think its safe to assume that this will be a prescription type of CBD and not the CBD that you can pick up at the local grocery store or holistic awareness shop. This will be a real pharma product. IMO.
Looks like New Website Coming soon:

Company details
Website
http://www.gcanrx.com

Headquarters
Baltimore, Maryland

Year founded
2018

Company type
Public Company

Company size
2-10 employees

Specialties

cannabis technology, biotechnology, biopharmaceutical, and delivery systems.

GCAN! yes we Cannabis

GCANRx is a biotech company and developer of innovative delivery systems for the Cannabis industry. The company has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery use in the Cannabis field. The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and nutraceuticals when compared to traditional methods of enteral administration. GCANRx is a fully reporting company, and publicly traded under the ticker symbol GCAN.
There are many benefits of using topical CBD patches to deliver cannabinoids such as cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). Some of the advantages of CBD patches include:

Avoidance of first-pass effect

Simple, convenient

Long duration of action - 8 hours

Controlled, constant administration

Targeted delivery

No interference with gastric and intestinal fluids

Available in 25 mg, 50 mg and 100 mg strengths

https://greatercannabiscompany.com/wp-content/uploads/2018/08/GCAN-8-6-2018-PR.pdf